Giredestrant
CAS No. 1953133-47-5
Giredestrant ( GDC-9545 )
Catalog No. M23885 CAS No. 1953133-47-5
Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain.?Giredestrant has anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 210 | In Stock |
|
5MG | 260 | In Stock |
|
10MG | 417 | In Stock |
|
25MG | 785 | In Stock |
|
50MG | 1251 | In Stock |
|
100MG | 1962 | In Stock |
|
200MG | 2673 | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGiredestrant
-
NoteResearch use only, not for human use.
-
Brief DescriptionGiredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain.?Giredestrant has anti-tumor activity.
-
DescriptionGiredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain.?Giredestrant has anti-tumor activity.?Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist.?
-
SynonymsGDC-9545
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorER
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1953133-47-5
-
Formula Weight522.6
-
Molecular FormulaC27H31F5N4O
-
Purity>98% (HPLC)
-
SolubilityDMSO:100mg/mL (191.37 mM; Need ultrasonic)
-
SMILESC[C@H](Cc1c2[nH]c3c1cccc3)N(CC(CO)(F)F)[C@@H]2c(c(F)cc(NC1CN(CCCF)C1)c1)c1F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.C Metcalfe, et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes
molnova catalog
related products
-
Etonogestrel
Etonogestrel is a steroidal progestin used in hormonal contraceptives.
-
Segetalin B
Segetalin B is a natural product from Vaccaria segetalis (Neck.) Garcke, has estrogen-like activity.
-
Medicarpin
(+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action.